| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
32,590,000 |
| Market
Cap: |
148.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1 - $7.68 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 22.2 |
| Insider 6 Months : 22.8 |
| Insider 3/6 Months : 45.2 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PepGen is a clinical-stage biotechnology company. Co.'s primary product candidate is PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) peptide conjugated to a phosphorodiamidate morpholino oligomers (PMO) therapeutic cargo, which it is developing for the treatment of Duchenne muscular dystrophy (DMD) patients with mutations amenable to an exon 51-skipping approach. Co. is developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of myotonic dystrophy type 1. Co.'s second EDO therapeutic candidate for the treatment of DMD, and third product candidate, PGN-EDO53, is an EDO peptide-conjugated PMO designed to skip exon 53 of the dystrophin transcript.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
9,575,000 |
9,583,375 |
9,634,875 |
12,194,162 |
| Total Buy Value |
$30,640,000 |
$30,650,393 |
$30,711,668 |
$57,931,514 |
| Total People Bought |
2 |
3 |
4 |
4 |
| Total Buy Transactions |
2 |
3 |
5 |
7 |
| Total Shares Sold |
0 |
0 |
2,959 |
62,959 |
| Total Sell Value |
$0 |
$0 |
$4,971 |
$1,044,766 |
| Total People Sold |
0 |
0 |
2 |
4 |
| Total Sell Transactions |
0 |
0 |
2 |
15 |
| End Date |
2025-07-27 |
2025-04-25 |
2024-10-25 |
2023-10-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oxford Sciences Innovation Plc |
Former 10% Owner |
– – – |
2025-09-30 |
4 |
B |
$3.20 |
$640,000 |
D/D |
200,000 |
4,955,388 |
2.44 |
-3% |
|
| Shah Rajeev M. |
Director |
– • • |
2025-09-26 |
4 |
B |
$3.20 |
$30,000,000 |
I/I |
9,375,000 |
18,554,273 |
2.25 |
-11% |
|
| Streck Paul |
EVP, Head of R&D |
• • – |
2025-05-30 |
4 |
B |
$1.24 |
$10,393 |
D/D |
8,375 |
27,805 |
2.74 |
234% |
|
| Kasraian Kasra |
Chief Technical Officer |
• • – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
16,750 |
16,750 |
|
- |
|
| Mcarthur James G |
President and CEO |
• • – |
2025-04-17 |
4 |
B |
$1.36 |
$13,550 |
D/D |
10,000 |
113,913 |
2.81 |
-7% |
|
| Mcarthur James G |
President and CEO |
• • – |
2025-04-08 |
4 |
B |
$1.15 |
$47,725 |
D/D |
41,500 |
103,913 |
2.81 |
30% |
|
| Donnelly Noel |
Chief Financial Officer |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
23,283 |
24,956 |
|
- |
|
| Delena Mary Beth |
General Counsel |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
14,968 |
|
- |
|
| Streck Paul |
EVP, Head of R&D |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
19,430 |
19,430 |
|
- |
|
| Mcarthur James G |
President and CEO |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
60,719 |
62,413 |
|
- |
|
| Delena Mary Beth |
General Counsel |
• • – |
2025-02-26 |
4 |
AS |
$1.68 |
$2,406 |
D/D |
(1,432) |
1,568 |
|
-24% |
|
| Donnelly Noel |
Chief Financial Officer |
• • – |
2025-02-26 |
4 |
AS |
$1.68 |
$2,565 |
D/D |
(1,527) |
1,673 |
|
-24% |
|
| Delena Mary Beth |
General Counsel |
• • – |
2025-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
|
- |
|
| Donnelly Noel |
Chief Financial Officer |
• • – |
2025-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
3,200 |
|
- |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-25 |
4 |
AS |
$18.06 |
$136,741 |
D/D |
(7,571) |
0 |
|
-65% |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-25 |
4 |
OE |
$10.21 |
$77,300 |
D/D |
7,571 |
7,571 |
|
- |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-24 |
4 |
AS |
$18.01 |
$3,619 |
D/D |
(201) |
0 |
|
-66% |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-24 |
4 |
OE |
$10.21 |
$2,052 |
D/D |
201 |
201 |
|
- |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-18 |
4 |
AS |
$18.20 |
$229,804 |
D/D |
(12,625) |
0 |
|
-73% |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-18 |
4 |
OE |
$10.21 |
$128,901 |
D/D |
12,625 |
12,625 |
|
- |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-16 |
4 |
AS |
$18.00 |
$106,247 |
D/D |
(5,901) |
0 |
|
-76% |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-16 |
4 |
OE |
$10.21 |
$60,249 |
D/D |
5,901 |
5,901 |
|
- |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-12 |
4 |
AS |
$18.04 |
$59,331 |
D/D |
(3,288) |
0 |
|
-73% |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-12 |
4 |
OE |
$10.21 |
$33,570 |
D/D |
3,288 |
3,288 |
|
- |
|
| Mellion Michelle L |
Chief Medical Officer |
• • – |
2024-07-02 |
4 |
AS |
$18.07 |
$669 |
D/D |
(37) |
0 |
|
-69% |
|
68 Records found
|
|
Page 1 of 3 |
|
|
0.07 (1.56%) 
